Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | KDM5C | P41229 | 1/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | DDO | Q99489 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | PDE9A | O76083 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16465374 | 0.74 | PIM1 (0.42) | KDM5AKDM5CKDM5BKDM4EMAPT | |
| SCHEMBL13913155 | 0.74 | KDM5A (0.63) | KDM5AKDM5CKDM5BDAODDO | |
| SCHEMBL5809605 | 0.74 | RPA1 (0.49) | DAODDOKDM4EMAPTKMT2A | |
| SCHEMBL11619748 | 0.73 | AHR (0.49) | DAODDOKDM4EMAPTKMT2A | |
| SCHEMBL8897835 | 0.72 | GRIN2D (0.60) | DAODDOKDM4EMAPTKMT2A | |
| SCHEMBL11640297 | 0.72 | DAO (0.44) | DAODDOKDM4EMAPTKMT2A | |
| SCHEMBL23885152 | 0.71 | AHR (0.46) | KDM4EMAPTKMT2AGAAMEN1 | |
| SCHEMBL30254577 | 0.71 | AHR (0.46) | KDM4EMAPTKMT2AGAAMEN1 | |
| SCHEMBL11007640 | 0.71 | KMT2A (0.46) | DAODDOKDM4EMAPTKMT2A | |
| SCHEMBL8583717 | 0.70 | DAO (0.66) | DAODDOKDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3302060-B1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | UNIV KAOHSIUNG MEDICAL (TW) | 2020-02-12 | — | — | EP | claimed |
| US-20180214426-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-08-02 | — | — | US | claimed |
| EP-3302060-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | Kaohsiung Medical University (TW) | 2018-04-11 | — | — | EP | claimed |
| WO-2016191576-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE | DCB-USA LLC (US) | 2016-12-01 | — | — | WO | claimed |
| CN-111514144-B | Pyrazolo [4,3-c ] quinoline derivatives having inhibitory activity on bacterial glucuronidase | 高雄医学大学 | 2021-10-26 | — | — | CN | disclosed |
| EP-3662751-B1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE | UNIV KAOHSIUNG MEDICAL (TW) | 2021-10-13 | — | — | EP | disclosed |
| US-11135206-B2 | Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-10-05 | — | — | US | disclosed |
| CN-107708419-B | Pyrazolo [4,3-c ] quinoline derivatives having inhibitory activity on bacterial glucuronidase | 高雄医学大学 | 2021-08-27 | — | — | CN | disclosed |
| US-11052072-B2 | Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-07-06 | — | — | US | disclosed |
| CN-111514144-A | Pyrazolo [4,3-c ] quinoline derivatives having inhibitory activity on bacterial glucuronidase | 高雄医学大学 | 2020-08-11 | — | — | CN | disclosed |
| EP-3662751-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE | Kaohsiung Medical University (TW) | 2020-06-10 | — | — | EP | disclosed |
| US-20200113878-A1 | PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2020-04-16 | — | — | US | disclosed |
| EP-3302060-B1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | UNIV KAOHSIUNG MEDICAL (TW) | 2020-02-12 | — | — | EP | disclosed |
| US-20180214426-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-08-02 | — | — | US | disclosed |
| EP-3302060-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | Kaohsiung Medical University (TW) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016191576-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE | DCB-USA LLC (US) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214426-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE | UGT1A3, UGT1A1, GUSB | KDM5A 1202/4885KDM5C 738/4885KDM5B 1407/4885 |
| US-20200113878-A1 | PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase | UGT1A3, UGT1A1, GUSB | KDM5A 1202/4885KDM5C 738/4885KDM5B 1407/4885 |
| US-11052072-B2 | Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase | UGT1A3, UGT1A1, DPP3 | KDM5A 1125/4885KDM5C 692/4885KDM5B 1334/4885 |
| US-11135206-B2 | Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase | UGT1A3, UGT1A1, DPP3 | KDM5A 1125/4885KDM5C 692/4885KDM5B 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.